Mylan Agrees To Pay $73M To Settle Antitrust Claims Involving EpiPen
KANSAS CITY, Kan. — Mylan NV, Mylan Specialty LP and Mylan Pharmaceuticals Inc. (collectively, Mylan) have agreed to contribute $73 million to a settlement fund to end claims that they conspired...To view the full article, register now.
Already a subscriber? Click here to view full article